Research programme: STAT6 inhibitors - Astellas
Alternative Names: AS 1617612; AS-1517499; YM-341619Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma
- Class
- Mechanism of Action STAT6 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-asthma in Japan (PO)
- 26 Sep 2006 Preclinical trials in Allergic asthma in Japan (PO)